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Enhancing factor (EF), a growth regulatory molecule, isolated from mouse small intestines, has been well characterized in this laboratory. It 
increases the binding of epidermal growth factor in a unique manner via its own receptor. In the first 20 N-terminal amino acids sequenced, EF 
showed 50% homology to human Group II phospholipase A2 (PLA2). Here we propose that EF is yet another, unidentified isoform of PLA2 which 
regulates cell proliferation via modulation of EGF binding. To our knowledge, this is the first report implicating PLA2-II-like molecules in growth 
regulation. 
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1. INTRODUCTION 2. EXPERIMENTAL PROCEDURES 
Earlier we have reported the isolation, purification 
and characterization of a unique modulator of epider- 
ma1 growth factor from mouse small intestines [1,2]. 
Termed the enhancing factor (EF), the 14 kDa heat- and 
acid-stable protein was isolated based on its ability to 
increase the binding of EGF in the radioreceptor assay 
[l]. We have demonstrated earlier that EF binds to a 
membrane-associated receptor which is distinct from 
the EGF receptor [2]. Crude EF, obtained from acid- 
soluble proteins extracted from small intestines, was 
purified to homogeneity following gel permeation 
chromatography on BioGel PlOO column and 2 cycles 
of reverse-phase HPLC on a p-Bondapak Cl8 column 
[3]. In this paper we report the further purification of 
EF on a cation-exchange column on HPLC and the 
partial amino acid sequence obtained on an automated 
gas-phase sequencer. The first 20 amino acids in the 
sequence from the N-terminal end of the protein 
showed considerable homology to the phospholipase 
A2 (PLA2) enzyme, specially to the mammalian group 
II PLA2 [4,5]. Various laboratories have reported that 
PLA2s are involved in cellular arachidonic acid release 
and inflammatory reactions [4-61. However, the pres- 
ence of group II PLA2 in small intestines uggests that 
they may not only be involved in inflammatory reac- 
tions but may have an additional, as yet unidentified 
physiological role. 
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2.1. Purification of EF 
Acid-soluble proteins were extracted from mouse small intestines 
and purified as described earlier [3]. To obtain sequencing rade pro- 
tein, reverse-phase HPLC (RP-HPLC)-purified EF was further passed 
over a cation-exchange HPLC (CE-HPLC) column (Protein-Pak SP 
5PW, Waters). The column was equilibrated in 0.1 M sodium phos- 
phate buffer, pH 6.6 (SPB) and lOOpug of protein injected. The column 
was washed for 10 min with SPB and the bound protein was eluted 
with a 1 M NaCl gradient. 5 pg of protein from each peak eluted from 
the column was tested for enhancing activity in the A431-“‘1-EGF 
binding radioreceptor assay as described earlier [l]. 
2.2. Sequencing of EF 
A partial amino acid sequence was obtained on an automated gas 
phase microsequencer (model 477A, Applied Biosystems). The first 20 
N-terminal amino acids sequence was subjected to homology search 
against protein sequences in the EMBL data bank. 
2.3. Assay for phospholipase A2 
The method of Habermann and Hardt [6] was followed to assay the 
PLA2 activity. Briefly, 0.6% agarose in 0.05 M sodium acetate buffer, 
pH 7.5 was mixed with 0.4 ml egg yolk suspension (1 part fresh egg 
yolk mixed with 3 parts 0.85% saline, centrifuged at 2,000 rpm and 1 
ml aliquots stored at -20°C) and 0.25 ml of 0.01 M CaCl,. The mixture 
was poured in 100 mm plates and wells punched in the agarose. 
Standard PLA2 and the test samples were suspended in saline contain- 
ing 0.1% BSA, added to different wells and the plates incubated at 
50°C for 20 h. Formation of clear plaques around the wells indicated 
PLA2 activity. 
3. RESULTS 
RP-HPLC purified EF, when passed over a cation- 
exchange column gave 3 minor and one major peak 
(Fig. 1). 5 pg protein equivalent from each peak was 
tested in the radioreceptor assay as described earlier [ 11. 
Protein eluting at 18.77 min and 19.75 min showed 
235% and 285% EGF binding which means 135% and 
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RETENTION # EGF 
flME(min) BINDING 
2.52 111 
14.50 I05 
18.77 235 
IQ. 75 285 
CONTROL 100 
Fig. 1. HPLC profile of purified EF run on a cation-exchange column, 
SP 5PW (Waters), as described. The retention time (min) is marked 
on every peak and the roman numbers designate the peak numbers. 
5 pg equivalent protein from each peak was tested in the ra~oreceptor 
assay using ‘*‘I-EGF and fixed A431 cells [I], Percentage of specific 
bound lz51-EGF is shown in the Table (inset). (Counts obtained in the 
control wells where cells were incubated with ““I-EGF alone were 
considered as 100% bound lz51-EGF.) 
185% enhanced activity, respectively (since control is 
considered as 100% EGF binding, Fig. 1, inset). When 
run on an SDS-PAGE and silver-stained, proteins in 
both peaks showed identical bands with the same mobil- 
ity (data not shown). Thus, both proteins appear to be 
the same with a slightly different ionic charge. The rea- 
son for this is not known. However, more than 90% of 
the protein eluted in the 19.75 min peak. This was se- 
quenced on an automated protein sequencer. 
The sequence of the first 20 N-terminal amino acids 
is shown in Fig. 2 along with the sequences of the related 
proteins. EF showed 50% homology to human synovial 
fluid PLA2 [4], human cartilage PLA2 [5] and Vipera 
aspis snake venom PLA2 [7]. Other mammalian PLA2 
including porcine intestinal PLA2 [8], bovine pancreatic 
PLA2 [9] and rat membrane-associated PLA2 [lo] 
showed 3045% homology to EF. 
sequence % homology 
Fig. 2. Comparison of first 20 N-terminal ammo acid sequence of EF 
with human PLA2 [4,5], snake venom PLA2 [7], rat PLA2 [IO], porcine 
PLA2 [3] and Bovine PLA2 [S]. Residues which are identical between 
EF and any of the other proteins arc boxed. 
EF was tested for PLA2 enzyme activity using egg- 
lecithin embedded in agarose as the substrate. EF 
showed PLA2 activity as seen by the clear plaques 
around the sample wells (Fig. 3). The activity was much 
lower than that compared to snake venom PLA2. Bo- 
vine pancreatic PLA2 (Sigma) did not show comparable 
activity. However, since this was a crude assay, its activ- 
ity was checked in the PLA2 assay using mixed micellar 
substrate of [‘4C]phosphatidyl choline and deoxycho- 
late, in Dr. Anil ~ukherjee’s laboratory at NICHDI 
NIH, Bethesda, USA. CE-HPLC-purified EF was 
found to have high PLA2 activity at a dilution of 600 
ng/ml (personal communication). Snake venom PLAZ, 
when tested in the radioreceptor assay showed en- 
hanced activity comparable to EF (data not shown). 
Neither bovine nor porcine pancreatic PLA2 showed 
enhanced activity. 
4. DISCUSSION 
EF is a 14 kDa molecule isolated from mouse small 
intestines based on its ability to increase the binding of 
EGF in the radioreceptor assay [l-3]. Our earlier stud- 
ies, using antibodies raised against EF, have shown that 
partially purified EF binds to labelled EGF in a cell-free 
system, in a dose-dependent manner [2]. Data on the 
Scatchard plot analysis have shown that pretreatment 
of cells with EF results in an increase in the number of 
binding sites for EGF without an apparent change in 
the affinity [2]. We have also demonstrated that EF 
binds to a 100 kDa cell membrane receptor on A431 
cells which is distinct from the EGF receptor [2]. Prelim- 
inary studies in our laboratory indicate that the receptor 
Fig. 3. Assay for PLA2 activity in agarose plates was carried out as 
described. Samples loaded in the wells were as follows: 1, snake venom 
PLA2 (10 ng); 2, snake venom PLA2 (20 ng); 3. intestinal crude extract 
(170 pg); 4. Biogel purified-EF* (100 c(g); 5, RP-HPLC (first cycle)- 
purified EF* (10 pg); 6, RP-HPLC (second cycle)-purified EF* (10 
pg); 7 and 8, CE-HPLC- purified EF (two different batches, 15 pg 
each); 9. distilled water (control); lr), bovine pancreatic PLA2 (Sigma, 
30 pg). 
*Prepared as described in reference 1 and 3. 
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could be a heparan-sulphate proteoglycan located on 
the cell membrane. 
Immunohistochemically, EF was found to be local- 
ized specifically in the Paneth cell, situated at the base 
of the villi, adjacent to the stem cell population, in the 
small intestines [l l-131. Immunoreactive EF was not 
found to be present in large amounts in any other tissue. 
Small amounts of EF were found in stomach, proximal 
colon and immature hair follicles in newborn mouse 
skin [12,13]. In vitro, EF induces anchorage-independ- 
ent growth of normal rat fibroblasts in the presence of 
EGF and also stimulates [3H]thymidine incorporation 
in NR6 cells (devoid of functional EGF receptors) in the 
presence of EGF [2]. In vivo, EF gene appears to be 
expressed in mouse regenerating liver as well as in hy- 
perplastic oesophageal epithelium (unpublished obser- 
vations). From these data, we have concluded that EF 
plays a role in cell proliferation by increasing the bind- 
ing of EGF to the cells and thereby modulating its 
action. 
In the present study we report that the EF protein is 
yet another member of the PLA2 family as the first 20 
N-terminal amino acids sequence shows 40-50% ho- 
mology to PLA2 from different sources (Fig. 2). Also 
purified EF showed lipid hydrolysing activity (Fig. 3). 
On the other hand, snake venom PLA2, but not bovine 
or porcine PLA2 showed enhanced activity in the radi- 
oreceptor assay. 
PLA2 are widely distributed enzymes which catalyse 
fatty acid release from the ~2-2 position of glycero- 
phospholipids [14]. Mammalian PLA2 have been di- 
vided into 2 main groups based on their primary struc- 
ture [15]. Mammalian group I PLA2 (PLAZI) is mainly 
secreted from pancreas as a digestive enzyme [ 16,171. 
Recently, Arita et al. [18] have reported that PLAZI has 
a novel proliferative effect in Swiss 3T3 cells via specific 
binding sites, possibly unrelated to its phospholipid hy- 
drolysing activity. They have also reported that PLA2-I 
plays a role in the migration of vascular smooth muscles 
via specific binding sites [19]. PLA2-I has also been 
shown to be present in bovine adrenal medulla [20], rat 
gastric mucosa and lung [21] and rat glandular stomach 
[22]. PLA2s from group II (PLA2-II) are involved in 
cellular arachidonic acid release and inflammation 
[4,5,23]. PLA2-II have been reported to be present in rat 
platelets [22], rat spleen [lo], human placenta, synovial 
fluid [4,24,25] as well as in human articular cartilage [5]. 
Presence of PLA2-like EF in the small intestines sug- 
gests that i has additional, yet unidentified physiologi- 
cal function. 
Based on our studies we propose that EF is an 
isoform of PLAZII, present in large amounts in the 
Paneth cells and it plays a crucial role in cell prolifera- 
tion by modulating the binding of EGF. EF could bind 
to its own membrane receptor and in turn offer a bind- 
ing site for EGF. Other PLA2-IIs like snake venom 
PLA2, rat platelet PLA2 and human synovial fluid 
PLA2 may function in a similar manner. Such mole- 
cules which regulate growth factor binding to cells may 
be important in tissues with high cell turnover. Lokesh- 
war et al. [26] have reported that basic proteins such as 
protamine increase EGF binding to high- as well as 
low-affinity receptors on cells by activating cryptic EGF 
receptors. EF could act via a similar mechanism. How- 
ever, that would not explain the increase in DNA syn- 
thesis brought about by EF and EGF added together 
in NR6 (EGF receptorless) cells as reported earlier [2]. 
Whether the lipid hydrolysing enzymatic action is neces- 
sary and sufficient for the enhancing activity is now 
being investigated. 
To our knowledge this is the first report implicating 
PLA2-II-like molecules in growth regulation. 
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